GlycoFix-3 (Structurally and Functionally Repaired Endothelial Glycocalyx, 3rd Edition)

GlycoFix-2 is a chemical formulation that repairs blood vessel linings to prevent heart diseasesGlycoFix-2: Chemical Repair of Blood Vessel Linings for Heart Disease PreventionBackground
The endothelial glycocalyx is a sugar mesh coat that serves as a protective barrier for endothelial cells, such as blood vessels. The endothelial glycocalyx can degrade over time with exposure to shear, circulating enzymes and reactive oxygen species. A compromised glycocalyx exposes blood vessels to harmful substances that contribute to plaque formation, a significant contributor to cardiac events like heart attack and stroke. The need for early intervention technologies is highlighted by the significant global burden of vascular diseases. Current treatments like statins or surgeries focus on advanced stages of heart disease, with few options available for early-stage intervention. A focus on the earlier stages of vascular diseases can potentially prevent the onset or lessen the severity of cardiovascular events. Currently, there are no pharmaceuticals that directly target the endothelial glycocalyx.

Technology Overview
GlycoFix-2 is a novel chemical formulation containing heparan sulfate (HS) and sphingosine-1-phosphate (S1P) derivatives. It aims to replenish the endothelial glycocalyx, which is crucial for protecting blood vessels. The HS and S1P derivatives are selected for their established clinical usage, stability, and cost-effectiveness. Preliminary studies indicate that GlycoFix-2 can effectively repair damaged endothelial glycocalyx, thus restoring endothelial function and potentially delaying the progression of atherosclerosis and subsequent cardiovascular conditions. This formulation represents a first line of defense in vascular health, using a method that is preparable for multi-route administration and compatible with medical devices.

Benefits
Directly repairs endothelial glycocalyx, preventing vascular degradation
Reduced risk of cardiac events
Utilizes clinically established and biologically derived components
Cost-effective production
Applications
Intravenous administration or Oral administration to patients with increased inflammation due to disease or surgery
Stent coating to aid endothelial cell recovery after deployment
Incorporation into circulating nanoparticle or immobilized biomaterial drug carriers
 

Opportunity
Seeking licensee/industry partner/funding.

Seeking
Seeking investment
Licensing
Commercial partner
Development partner


IP Status
Provisional patent

Patent Information: